These stimuli-switchable nanoparticles coated with the cleavable outer polymer coatingmultifunctional peptides may afford a new platform for anticancer drugmiR. These nanoparticles possess characteristics of environmental response, active targeting,gene/chemo combinatorial therapeutics, thus providing spatiotemporal control of posttranｓｃｒｉｐｔional gene regulation, smart nuclear/mitochondrial localization,simultaneous inhibition of multiple progression pathways of tumor cells for enhancing antitumor efficacysafety of cancer therapy.

Ninety percent of human diseases are related to abnormal inflammation. WJM team has successfully developed a new monoclonal antibody that can inhibit a key inflammation protein. Animal experiments have accumulated more than ten disease modes, including a variety of solid tumors, fibrosis, degenerativecardiovascular diseases. This antibody is qualified as an orphan drug for the treatment of IPF. New coronary pneumonia has greatly increased the demand for pulmonary fibrosis treatment,has also become an important target for mergersacquisitions of global pharmaceutical companies.

Chronic wound infection is a leading cause of mortality in injured patients worldwide. At present, available systemic antibiotic treatments have an insufficient tissue penetration ability and allow the development of antibiotic-resistant pathogens. The identification of therapeutic agents with wound healing and antimicrobial functions is necessary to heal the wound and cure infections. Our report shows that the antimicrobial peptide (AMP) Epinecidin-1 (Epi-1) efficiently heals MRSA-infected heat burn injuries and provides protection from infection in mouse and pig model. Our results demonstrate that the biomaterial Epi-1 heals wounds through increasing epithelial cell proliferation, vascularization, and the formation of collagen and controls MRSA infection-mediated sepsis in pigs.

X-ray diffraction technology is used to analyze the drug efflux pump, ST50, form S. Typhi. The drug efflux mechanism for multiple drug resistant (MDR) S. Typhithe potential location for antigen of market-based typhoid detection reagent are understood through this ST50 structure. It could help develop the more effective typhoid detection reagentthe new antibiotics against MDR S. Typhi.